Home Cart 0 Sign in  
X

[ CAS No. 5451-40-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 5451-40-1
Chemical Structure| 5451-40-1
Chemical Structure| 5451-40-1
Structure of 5451-40-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5451-40-1 ]

Related Doc. of [ 5451-40-1 ]

Alternatived Products of [ 5451-40-1 ]

Product Details of [ 5451-40-1 ]

CAS No. :5451-40-1 MDL No. :MFCD00077725
Formula : C5H2Cl2N4 Boiling Point : -
Linear Structure Formula :- InChI Key :RMFWVOLULURGJI-UHFFFAOYSA-N
M.W : 189.00 Pubchem ID :5324412
Synonyms :

Safety of [ 5451-40-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 5451-40-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5451-40-1 ]
  • Downstream synthetic route of [ 5451-40-1 ]

[ 5451-40-1 ] Synthesis Path-Upstream   1~59

  • 1
  • [ 5451-40-1 ]
  • [ 2002-59-7 ]
Reference: [1] Patent: US2697709, 1952, ,
  • 2
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
YieldReaction ConditionsOperation in experiment
78% With potassium carbonate In N,N-dimethyl-formamide at 0℃; for 5 h; 2,6-Dichloro-9-methyl-9H-purine (15b). To a solution of 2,6-dichloro-9H-purine (0.120 g, 0.635 mmol) in anhydrous DMF (1.0 rriL) was added K2CC>3 (0.270 g, 1.95 mmol) followed by iodomethane (0.20 mL, 3.21 mmol) at 0 °C. The reaction mixture was stirred for 5 h at 0 °C, quenched with water and extracted with EtOAc. The organic layers were combined, washed with brine, dried (MgS04), concentrated, and purified by chromatography on Si02 (hexanes, 100percent, to EtOAc, 100percent) to yield 15b (83.0 mg, 0.409 mmol, 64percent yield) as a colorless solid: IR (ATR, neat) 3067, 1554, 1360, 1333, 1223, 1147 cm 1; NMR (CDCI3, 600 MHz) δ 8.09 (s, 1 H), 3.89 (s, 3 H); 13C NMR (CDCI3, 150 MHz) δ 153.3, 152.7, 151.3, 146.4, 130.4, 30.4.
43% With potassium carbonate In acetone for 1 h; 2,6-Dichloropurine (30 g, 159 mmol) was dissolved in acetone (200 mL) and potassium carbonate (33 g, 238 mmol) was added.
Methyliodide (11.9 mL, 190 mmol) was added and the mixture was stirred for one hour followed by concentration in vacuo.
The remaining residue was stirred with water.
The white precipitate was collected by filtration to give a mixture of 2,6-dichloro-9-methyl-9H-purine and 2,6-dichloro-9-methyl-9H-purine (28 g, 3:2).
The mixture of the two isomers were recrystallised from ethyl acetate giving 2,6-dichloro-9-methyl-9H-purine (5.7 g 18percent).
The mother liquid was concentrated in vacuo and purified by flash chromatography (ethyl acetate/heptane as eluent) to give 2,6-dichloro-9-methyl-9H-purine (14 g, 43percent) as a white solid.
21% With potassium carbonate In acetonitrile at 0 - 20℃; Iodomethane (23 g, 162.04 mmol, 1.53 equiv) was added dropwise into a mixture of potassium carbonate (30 g, 215.50 mmol, 2.04 equiv), 2,6-dichloro-9H-purine (20 g, 105.82 mmol, 1.00 equiv) in 2 L of acetonitrile at 0 °C and then stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product was purified by re-crystallization from PE:DCM (10: 1) to give 4.5 g (21percent) of 2,6-dichloro-9-methyl-9H-purine as a yellow solid.
Reference: [1] Patent: WO2014/189830, 2014, A1, . Location in patent: Page/Page column 35
[2] ACS Medicinal Chemistry Letters, 2012, vol. 3, # 12, p. 985 - 990
[3] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 12, p. 3486 - 3490
[4] Patent: US2011/237607, 2011, A1, . Location in patent: Page/Page column 6; 7
[5] Patent: WO2016/91916, 2016, A1, . Location in patent: Page/Page column 66
[6] Phytochemistry (Elsevier), 1986, vol. 25, # 2, p. 303 - 310
[7] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 1126 - 1134
  • 3
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
  • [ 2273-93-0 ]
YieldReaction ConditionsOperation in experiment
66% With potassium carbonate In acetonitrile at 20℃; for 70 h; 2, 6-dichloropurine (5.0 gram), methyl iodide (1. 1 eq. , 1.81 mL) and K.) C03 (1.2 eq. , 4.39 gram) were dissolved in 200 mL of MECN. After stirring for 70 hours at 20°C, the MECN was evaporated. Both isomers were separated by column chromatography using CH2C12/MEOH (90/10). Yield: 3.55 g (66percent) of intermediate 33 and 1.61 g (30percent) of intermediate 40.
66% With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃; for 0.5 h; Inert atmosphere Step 1: Preparation of 2,6-dichloro-9-methyl-9H-purine and 2,6-dichloro-7-methyl-7H-purine (a-2) To a solution of 2,6-dichloropurine (1.10 g, 5.82 mmol) in anhydrous THF (5.0 mL) was added tetra-n-butylammonium fluoride (0.58 mL, 10.58 mmol, 1.8 eq; 1M in THF). Methyl iodide (0.40 mL, 6.42 mmol, 1.1 eq) was added, and the reaction mixture was stirred at RT under N2 for 30 minutes. The reaction mixture was then diluted with ethyl acetate (250 mL). The organic layer was washed with aqueous saturated sodium thiosulfate solution, water and brine, then dried (Na2SO4), filtered and evaporated in vacuo. The resultant residue was purified by column chromotagraphy (Si-PPC, gradient 5 to 100percent ethyl acetate in hexane) to give 2,6-dichloro-9-methyl-9H-purine (a-2) as a white solid (780 mg, 66percent) followed by gradient 0 to 30percent methanol in ethyl acetate to give 2,6-dichloro-7-methyl-7H-purine (a-3) as a white solid (346 mg, 29.3percent). 1H NMR of 2,6-dichloro-9-methyl-9H-purine (DMSO-d6, 400 MHz) δ ppm 8.75 (s, 1H), 3.83 (s, 3H). 1H NMR of 2,6-dichloro-7-methyl-7H-purine (DMSO-d6, 400 MHz) δ ppm 8.80 (s, 1H), 4.09 (s, 3H).
43%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil at 0℃; for 0.5 h; Inert atmosphere
Stage #2: at 0 - 25℃; for 17 h; Inert atmosphere
Intermediate 12.2,6-Dichloro-7-methyl-7H-purine To a solution of 2,6-dichloro-7H-purine (1.05 g, 5.56 mmol) in THF (8 mL) at 0 °C under nitrogen was added NaH (60percent in mineral oil, 525 mg, 13.1 mmol) in one portion and, after stirring for 30 min at 0 °C, iodomethane (0.38 mL, 6.12 mmol) was added. The mixture was stirred at 0 °C for 1 h and then at room temperature for 16 h. After this time, the reaction mixture was diluted with EtOAc and washed with water and brine. The organic layer was concentrated under reduced pressure and the residue obtained was purified by column chromatography (silica, 0–30percent EtOAc in CH2Cl2) to provide isomers 2,6-dichloro-9-methyl-9H-purine (491 mg, 43percent) and 2,6-dichloro-7- methyl-7H-purine (312 mg, 28percent): ESI MS (M+H) 203; 2,6-dichloro-9-methyl-9H-purine 1H NMR (300 MHz, DMSO-d6) G 8.69 (s, 1H), 3.83 (s, 3H) and 2,6-dichloro-7-methyl- 7H-purine 1H NMR (300 MHz, DMSO-d6) G 8.81 (s, 1H), 4.07 (s, 3H).
11%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil for 0.5 h; Cooling with ice
Sodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice-cooled solution of 2,6-dichloropurine (10.0 g, 52,9 mmol) in tetrahydrofuran (75 ml_) and the mixture was stirred for 30 min. Methyl iodide (3.29 ml_, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7/-/-puhne (1.19 g, 11 percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl- 9H-puhne (3.0 g, 28percent)
28%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil for 0.5 h;
Sodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice-cooled solution of 2,6-dichloropurine (10.0 g, 52,9 mmol) in tetrahydrofuran (75 mL) and the mixture was stirred for 30 min. Methyl iodide (3.29 mL, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7H-purine (1.19 g, 11percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl-9H-purine (3.0 g, 28percent).

Reference: [1] Patent: WO2005/28479, 2005, A2, . Location in patent: Page/Page column 58
[2] Patent: US2011/86841, 2011, A1, . Location in patent: Page/Page column 25
[3] Patent: WO2016/115434, 2016, A1, . Location in patent: Page/Page column 222; 223
[4] Patent: WO2010/34707, 2010, A1, . Location in patent: Page/Page column 15
[5] Patent: US2011/251217, 2011, A1, . Location in patent: Page/Page column 6-7
[6] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 15, p. 4622 - 4626
[7] Patent: WO2010/34706, 2010, A1, . Location in patent: Page/Page column 15
[8] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 18, p. 5097 - 5104
  • 4
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
YieldReaction ConditionsOperation in experiment
48% With potassium carbonate In acetonitrile at 20℃; for 24 h; 2,6-Dichloropurine (24) (2.00 g, 10.6 mmol), methyl iodide (1.65 g, 11.6 mmol) and potassium carbonate (1.75 g, 12.7 mmol) were dissolved in acetonitrile (50 mL). After stirring for 24 h at room temperature the acetonitrile was removed under vacuum. The crude material was purified with column chromatography (hexane: ethyl acetate 1:1). The title compound 26 was obtained as white solid (1.04 g, 48percent), mp: 150-153 °C (lit.10 151-153 °C). 1H NMR (400 MHz, CDCl3) 8.11 (s, 1H), 3.93 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 153.5 (C), 153.1 (C), 151.8 (C), 146.3 (CH), 130.7 (C), 30.5 (CH3). LRMS: m/z (ESI 20 V) 203.2 (MH+, 100).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 11, p. 3427 - 3433
[2] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 20, p. 9268 - 9275
  • 5
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
Reference: [1] Patent: WO2008/107368, 2008, A1, . Location in patent: Page/Page column 33
  • 6
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
  • [ 2273-93-0 ]
YieldReaction ConditionsOperation in experiment
27% With potassium carbonate In acetone at 20℃; for 1.5 h; To a solution of dichloropurine 27 (1.36 g, 7.20 mmol) was dissolved in acetone (22.7 mL) and potassium carbonate (1.49 mg, 10.8 mmol) was added at room temperature. Methyl iodide (537 i.il, 8.67 mmol) was added and the mixture was stirred for 1.5 h at room temperature. The reaction mixture was concentrated, water was added to the residue and stirred stirred for 5 mm, and then extracted with ethyl acetate (2 x 100 ml). The combined organic layers were dried on Mg504, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography. Compound 29 was the major product formed (952 mg, 65percent) and was obtained as off-white solid and compound 28 was the minor product (389 mg, 27percent) aslo isolated pure as an off-white solid; these results are consistant with the literature (for example WO 2010/034706)
30% With potassium carbonate In acetonitrile at 20℃; for 70 h; Example 1; Synthesis of 2,6-dichloro-7-methyl-7H-purine from 3,7 dimethyl-1H-purine 2,6(3H,7H) dione (theobromine) (a-2) 2,6 dichloro-7-methyl-7H-purine was prepared from theobromine (a-1) in 10percent yield following the procedure of Uretskaya,G. Ya., Rybinka, E. I., and Men'shikov, G. P. Zh. Obshch. Ki., 1960, 30, 327 with the modification of N,N, diethylaniline disclosed by Stanovik, B. et at in the Australian Journal of Chemistry, 1981, 34, 1729. 1H NMR was identical in all respects to the material prepared by alkylation of commercially available 2,6 dichloropurine with base and iodomethane. For example, the procedure reported by Feng et al. (WO2004/087053) utilizes 60percent NaH as base, dimethylformamide (DMF) as the solvent and iodomethane yielded a 1:1 mixture of the N-7/N-9 methylated products which were separated via silica chromatography. The procedure reported by Lewi et et al (WO2005/028479 A2) utilizes potassium carbonate as the base, acetonitrile as solvent (rt 70 h) and iodomethane and yielded a 2:1 isolated yield of methylated purines after silica chromatography (60percent yield N9Me/30percent yield N-7 Methylated). Similarly acetone can replace acetonitrile as the solvent and after refluxing with potassium carbonate and iodomethane for 24 h a 3:1 mixture of N9/N7 is obtained. The N-7 methylated product was isolated in 16.3percent purified yield after silica chromatography. A report by Chi-Huey Wong et al. (see, Bioorg Med Chem 13 (2005) 4622-4626) utilizes tetrabutylammonium fluoride as the base (1M solution THF) and iodomethane to give similarily a 3:1 ratio of the N-9/N-7 methylated purines which could be separated by silica chromatography. 1H NMR (400 MHz, DMSO d&6) 8.79 (s, 1H, H8), 4.06 (s, 3H, N7Me).
11%
Stage #1: With sodium hydride In tetrahydrofuran at 0℃; for 0.5 h;
Example 12,6-Dichloro-9-methyl-9/-/-purine and 2,6-Dichloro-7-methyl-7/-/-purineSodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice- cooled solution of 2,6-dichloropuhne (10.0 g, 52.9 mmol) in tetrahydrofuran (75 ml_) and the mixture was stirred for 30 min. Methyl iodide (3.29 ml_, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7/-/-purine (1.19 g, 11 percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl-9/-/-purine (3.0 g, 28percent).
Reference: [1] Patent: WO2018/137036, 2018, A1, . Location in patent: Paragraph 00231; 00232
[2] Patent: US2011/86840, 2011, A1, . Location in patent: Page/Page column 29
[3] Patent: WO2008/116909, 2008, A1, . Location in patent: Page/Page column 22
  • 7
  • [ 5451-40-1 ]
  • [ 7013-21-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 9, p. 2877 - 2882
  • 8
  • [ 5451-40-1 ]
  • [ 7013-21-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 11, p. 3427 - 3433
  • 9
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
  • [ 2273-93-0 ]
YieldReaction ConditionsOperation in experiment
66% With potassium carbonate In acetonitrile at 20℃; for 70 h; 2, 6-dichloropurine (5.0 gram), methyl iodide (1. 1 eq. , 1.81 mL) and K.) C03 (1.2 eq. , 4.39 gram) were dissolved in 200 mL of MECN. After stirring for 70 hours at 20°C, the MECN was evaporated. Both isomers were separated by column chromatography using CH2C12/MEOH (90/10). Yield: 3.55 g (66percent) of intermediate 33 and 1.61 g (30percent) of intermediate 40.
66% With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃; for 0.5 h; Inert atmosphere Step 1: Preparation of 2,6-dichloro-9-methyl-9H-purine and 2,6-dichloro-7-methyl-7H-purine (a-2) To a solution of 2,6-dichloropurine (1.10 g, 5.82 mmol) in anhydrous THF (5.0 mL) was added tetra-n-butylammonium fluoride (0.58 mL, 10.58 mmol, 1.8 eq; 1M in THF). Methyl iodide (0.40 mL, 6.42 mmol, 1.1 eq) was added, and the reaction mixture was stirred at RT under N2 for 30 minutes. The reaction mixture was then diluted with ethyl acetate (250 mL). The organic layer was washed with aqueous saturated sodium thiosulfate solution, water and brine, then dried (Na2SO4), filtered and evaporated in vacuo. The resultant residue was purified by column chromotagraphy (Si-PPC, gradient 5 to 100percent ethyl acetate in hexane) to give 2,6-dichloro-9-methyl-9H-purine (a-2) as a white solid (780 mg, 66percent) followed by gradient 0 to 30percent methanol in ethyl acetate to give 2,6-dichloro-7-methyl-7H-purine (a-3) as a white solid (346 mg, 29.3percent). 1H NMR of 2,6-dichloro-9-methyl-9H-purine (DMSO-d6, 400 MHz) δ ppm 8.75 (s, 1H), 3.83 (s, 3H). 1H NMR of 2,6-dichloro-7-methyl-7H-purine (DMSO-d6, 400 MHz) δ ppm 8.80 (s, 1H), 4.09 (s, 3H).
43%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil at 0℃; for 0.5 h; Inert atmosphere
Stage #2: at 0 - 25℃; for 17 h; Inert atmosphere
Intermediate 12.2,6-Dichloro-7-methyl-7H-purine To a solution of 2,6-dichloro-7H-purine (1.05 g, 5.56 mmol) in THF (8 mL) at 0 °C under nitrogen was added NaH (60percent in mineral oil, 525 mg, 13.1 mmol) in one portion and, after stirring for 30 min at 0 °C, iodomethane (0.38 mL, 6.12 mmol) was added. The mixture was stirred at 0 °C for 1 h and then at room temperature for 16 h. After this time, the reaction mixture was diluted with EtOAc and washed with water and brine. The organic layer was concentrated under reduced pressure and the residue obtained was purified by column chromatography (silica, 0–30percent EtOAc in CH2Cl2) to provide isomers 2,6-dichloro-9-methyl-9H-purine (491 mg, 43percent) and 2,6-dichloro-7- methyl-7H-purine (312 mg, 28percent): ESI MS (M+H) 203; 2,6-dichloro-9-methyl-9H-purine 1H NMR (300 MHz, DMSO-d6) G 8.69 (s, 1H), 3.83 (s, 3H) and 2,6-dichloro-7-methyl- 7H-purine 1H NMR (300 MHz, DMSO-d6) G 8.81 (s, 1H), 4.07 (s, 3H).
11%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil for 0.5 h; Cooling with ice
Sodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice-cooled solution of 2,6-dichloropurine (10.0 g, 52,9 mmol) in tetrahydrofuran (75 ml_) and the mixture was stirred for 30 min. Methyl iodide (3.29 ml_, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7/-/-puhne (1.19 g, 11 percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl- 9H-puhne (3.0 g, 28percent)
28%
Stage #1: With sodium hydride In tetrahydrofuran; mineral oil for 0.5 h;
Sodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice-cooled solution of 2,6-dichloropurine (10.0 g, 52,9 mmol) in tetrahydrofuran (75 mL) and the mixture was stirred for 30 min. Methyl iodide (3.29 mL, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7H-purine (1.19 g, 11percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl-9H-purine (3.0 g, 28percent).

Reference: [1] Patent: WO2005/28479, 2005, A2, . Location in patent: Page/Page column 58
[2] Patent: US2011/86841, 2011, A1, . Location in patent: Page/Page column 25
[3] Patent: WO2016/115434, 2016, A1, . Location in patent: Page/Page column 222; 223
[4] Patent: WO2010/34707, 2010, A1, . Location in patent: Page/Page column 15
[5] Patent: US2011/251217, 2011, A1, . Location in patent: Page/Page column 6-7
[6] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 15, p. 4622 - 4626
[7] Patent: WO2010/34706, 2010, A1, . Location in patent: Page/Page column 15
[8] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 18, p. 5097 - 5104
  • 10
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2273-93-0 ]
YieldReaction ConditionsOperation in experiment
22% With potassium carbonate In acetonitrile at 40℃; for 6 h; A mixture of 2,6-dichloro-7H-purine (5.0 g, 26.7 mmol), K2C03 (5.52 g, 40 mmol) and Mel (7.58 g, 53.4 mmol) in acetonitrile (50 mL) was heated to 40 °C for 6 hrs. The reaction was cooled to r.t., filtered, and concentrated to provide a crude mixture of regioisomeric products which were separated by column chromatography. The desired isomer, 2,6-dichloro-7-methyl-7H-purine, was isolated as a white solid white solid (1.2 g, 22percent).
Reference: [1] Patent: WO2015/175813, 2015, A1, . Location in patent: Paragraph 00425; 00426
  • 11
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2273-93-0 ]
Reference: [1] Organic Letters, 2016, vol. 18, # 1, p. 16 - 19
  • 12
  • [ 5451-40-1 ]
  • [ 74-88-4 ]
  • [ 2382-10-7 ]
  • [ 2273-93-0 ]
YieldReaction ConditionsOperation in experiment
27% With potassium carbonate In acetone at 20℃; for 1.5 h; To a solution of dichloropurine 27 (1.36 g, 7.20 mmol) was dissolved in acetone (22.7 mL) and potassium carbonate (1.49 mg, 10.8 mmol) was added at room temperature. Methyl iodide (537 i.il, 8.67 mmol) was added and the mixture was stirred for 1.5 h at room temperature. The reaction mixture was concentrated, water was added to the residue and stirred stirred for 5 mm, and then extracted with ethyl acetate (2 x 100 ml). The combined organic layers were dried on Mg504, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography. Compound 29 was the major product formed (952 mg, 65percent) and was obtained as off-white solid and compound 28 was the minor product (389 mg, 27percent) aslo isolated pure as an off-white solid; these results are consistant with the literature (for example WO 2010/034706)
30% With potassium carbonate In acetonitrile at 20℃; for 70 h; Example 1; Synthesis of 2,6-dichloro-7-methyl-7H-purine from 3,7 dimethyl-1H-purine 2,6(3H,7H) dione (theobromine) (a-2) 2,6 dichloro-7-methyl-7H-purine was prepared from theobromine (a-1) in 10percent yield following the procedure of Uretskaya,G. Ya., Rybinka, E. I., and Men'shikov, G. P. Zh. Obshch. Ki., 1960, 30, 327 with the modification of N,N, diethylaniline disclosed by Stanovik, B. et at in the Australian Journal of Chemistry, 1981, 34, 1729. 1H NMR was identical in all respects to the material prepared by alkylation of commercially available 2,6 dichloropurine with base and iodomethane. For example, the procedure reported by Feng et al. (WO2004/087053) utilizes 60percent NaH as base, dimethylformamide (DMF) as the solvent and iodomethane yielded a 1:1 mixture of the N-7/N-9 methylated products which were separated via silica chromatography. The procedure reported by Lewi et et al (WO2005/028479 A2) utilizes potassium carbonate as the base, acetonitrile as solvent (rt 70 h) and iodomethane and yielded a 2:1 isolated yield of methylated purines after silica chromatography (60percent yield N9Me/30percent yield N-7 Methylated). Similarly acetone can replace acetonitrile as the solvent and after refluxing with potassium carbonate and iodomethane for 24 h a 3:1 mixture of N9/N7 is obtained. The N-7 methylated product was isolated in 16.3percent purified yield after silica chromatography. A report by Chi-Huey Wong et al. (see, Bioorg Med Chem 13 (2005) 4622-4626) utilizes tetrabutylammonium fluoride as the base (1M solution THF) and iodomethane to give similarily a 3:1 ratio of the N-9/N-7 methylated purines which could be separated by silica chromatography. 1H NMR (400 MHz, DMSO d&6) 8.79 (s, 1H, H8), 4.06 (s, 3H, N7Me).
11%
Stage #1: With sodium hydride In tetrahydrofuran at 0℃; for 0.5 h;
Example 12,6-Dichloro-9-methyl-9/-/-purine and 2,6-Dichloro-7-methyl-7/-/-purineSodium hydride (60percent in mineral oil, 2.53 g, 63.5 mmol) was added to an ice- cooled solution of 2,6-dichloropuhne (10.0 g, 52.9 mmol) in tetrahydrofuran (75 ml_) and the mixture was stirred for 30 min. Methyl iodide (3.29 ml_, 52.9 mmol) was added drop-wise and the reaction mixture was stirred over night. Water was added and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over magnesium sulphate, filtered and concentrated in vacuo. Dichloromethane was added and undissolved material was collected by filtration. The crystalline compound turned out to be 2,6-dichloro-7-methyl-7/-/-purine (1.19 g, 11 percent) The filtrate was concentrated in vacuo and purified by flash chromatography (ethyl acetate/hepatane) to give 2,6-dichloro-9-methyl-9/-/-purine (3.0 g, 28percent).
Reference: [1] Patent: WO2018/137036, 2018, A1, . Location in patent: Paragraph 00231; 00232
[2] Patent: US2011/86840, 2011, A1, . Location in patent: Page/Page column 29
[3] Patent: WO2008/116909, 2008, A1, . Location in patent: Page/Page column 22
  • 13
  • [ 5451-40-1 ]
  • [ 100-46-9 ]
  • [ 39639-47-9 ]
YieldReaction ConditionsOperation in experiment
95% With triethylamine In butan-1-ol at 60℃; for 0.25 h; Synthesis of compounds 2-Chloro-6-benzylaminopurine (4); [00147] To a suspension of 2,6-dichloropurine (110 mg, 0.52 mmol) in n-butanol (3 mL), benzylamine (57 mg, 0.52 mmol) and triethylamine (72 mg, 0.79 mmol) was added. The mixture was stirred and heated at 60°C for 15 min. The resulting precipitate was filtered, washed with water (20 mL) and methanol (10 mL), and air-dried overnight. Compound 4 (130 mg, 95percent) was obtained as an off-white solid: mp 262°C; EI/MS (m/z (relative percent)): 259 (19, M+ ), 260 (14), 261 (17 percent), 106 (100), 91 (77); ]H NMR (400 MHz, DMSO) δ 8.15 (s, 1 H), 7.25-7.34 (m, 5 H), 4.66 (d, J = 6 Hz, 2 H) ; 13C NMR (100 MHz, DMSO) δ 155.0 (s) 153.1 (s), 150.7 (s), 140.2 (d, 1JC-H = 200 Hz ), 139.6 (s), 128.5 (d, ^ = 158 Hz, 127.5 (d, ^C-H = 157 Hz), 127.0 (d, ^C-H = 158 Hz) 118.1 (s), 43.4 (t, ^C-H = 139 Hz).
14 g With triethylamine In butan-1-ol at 90℃; for 3 h; Add in 250ml single mouth bottle2,6-dichloropurine(10g, 52.91mmol), n-butanol (150ml), heated to 90 ° C to dissolve,Add triethylamine (14 ml, 100.44 mmol),Benzylamine (6.7 ml, 61.36 mmol),After 10 minutes of reaction,A white solid precipitated and the reaction was continued for 3 hours, and then the heating was stopped.After cooling to 5-10 ° C, it was filtered. Wash with 100ml of water first,The triethylamine hydrochloride was removed and washed with 30 ml of 3 ethanol.Remove n-butanol and water, vacuum or dry at normal pressure,A white solid (Compound 3a, 2-chloro-6-(benzylamino)phosphonium) 14 g was obtained.
Reference: [1] Organic Process Research and Development, 2009, vol. 13, # 3, p. 641 - 644
[2] Synthetic Communications, 2010, vol. 40, # 12, p. 1856 - 1866
[3] Patent: WO2012/51296, 2012, A2, . Location in patent: Page/Page column 40
[4] Archiv der Pharmazie, 1999, vol. 332, # 6, p. 187 - 190
[5] Nucleosides, Nucleotides and Nucleic Acids, 2011, vol. 30, # 7-8, p. 503 - 511
[6] Tetrahedron Letters, 1998, vol. 39, # 13, p. 1827 - 1830
[7] Journal of Organic Chemistry, 1997, vol. 62, # 1, p. 201 - 203
[8] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 21, p. 2697 - 2702
[9] Patent: WO2016/11394, 2016, A1, . Location in patent: Page/Page column 120
[10] Patent: CN104936959, 2018, B, . Location in patent: Paragraph 0132; 0133
  • 14
  • [ 100-39-0 ]
  • [ 5451-40-1 ]
  • [ 39639-47-9 ]
Reference: [1] Journal of Medicinal Chemistry, 2008, vol. 51, # 3, p. 545 - 552
  • 15
  • [ 100-39-0 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
YieldReaction ConditionsOperation in experiment
94%
Stage #1: With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 0.5 h;
27.1 Preparation of 9-benzyl-2,6-dich.oro-9H-purine Potassium carbonate (2.07 g, 15 mmol) was added to a solution of 2,6-dichloro-9H- purine (945 mg, 5.0 mmol) in dimethylformamide (20 ml) and the mixture stirred at ambient temperature for 30 minutes. Benzyl bromide (1.2 ml, 10 mmol) was added and the mixture stirred overnight. Water was added and the resulting mixture extracted with ethyl acetate. The comined organic extracts were washed with water and brine, dried over magnesium sulphate, filtered and evaporated under reduced pressure. The residue was purified by automated flash chromatography (Presearch Combiflash Rf) on silica, with ethyl acetate in hexane ( 0percent to 80percent gradient) as eluent, to provide 9-benzyl- 2,6-dichloro-9H-purine as a white solid (876 mg, 94percent).Characterising data for the compound are as follows:1H NMR (400 MHz, CDCI3) δ 8.10 (1 H, s), 7.40 (5H, m), 5.40 (2H, s) ppm. 27.2 Preparation of 9-benzyl-2-chloro-6-trimethylstannyl-9H-purine
57% With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 16 h; 2,6-Dichloro-9H-purine (10.9 g, 60 mmol; purchased from Aldrich Chemical Co.) was dissolved in 200 ml_ dimethylformamide (DMF) and potassium carbonate (31.9 g, 230 mmol) was added. Benzyl bromide (13.7 ml_, 120 mmol) was added in portions and the whole stirred at room temperature under nitrogen for 16 hours. The mixture was filtered through a short plug of Arbocel.(R). and the filtrate was evaporated in vacuo <n="29"/>to give a yellow oil of the N7- (more polar) and N9-benzyl (less polar) purines. This oil was purified by silica gel chromatography using 1:2:10 ethylacetate:acetone:hexane as eluent to give the 9-benzyl-2,6-dichloro-9H-purine as a white solid (9.1 g, 57percent).
56% With potassium carbonate In dimethyl sulfoxide at 20℃; for 20 h; To a stirred solution of 2,6-dichloropurine (5.30 mmol, 1 eq) in 10 ml anhydrous DMSO at room temperature was added anhydrous potassium carbonate (6.34 mmol, 1.2 eq) and benzyl bromide (6.34 mmol, 1.2 eq). The reaction mixture was maintained at this temperature for 20 h. The reaction can be monitored using either TLC or LC/MS. The reaction mixture was poured into a beaker containing ice- cold water. The aqueous layer was acidified to pH 5-6. Extraction of the aqueous layer, using 3x75 ml portions of ethyl acetate, afforded the crude product. This was purified on the silica gel column (10-70percent ethyl acetate in petroleum ether, step- gradient), to give the desired compound in a yield of 56percent.
Reference: [1] Patent: WO2011/45561, 2011, A2, . Location in patent: Page/Page column 212
[2] Patent: WO2008/47201, 2008, A2, . Location in patent: Page/Page column 27-28
[3] Patent: WO2011/78795, 2011, A1, . Location in patent: Page/Page column 75
[4] Journal of Medicinal Chemistry, 1988, vol. 31, # 10, p. 2001 - 2004
[5] Patent: US4278675, 1981, A,
[6] Patent: WO2007/140233, 2007, A1, . Location in patent: Page/Page column 97
  • 16
  • [ 5451-40-1 ]
  • [ 100-51-6 ]
  • [ 79064-26-9 ]
YieldReaction ConditionsOperation in experiment
93% With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 0 - 20℃; Inert atmosphere General procedure: 2,6-Dichloro-9H-purine (15.8 mmol), an appropriate alcohol(31.7 mmol), and triphenylphosphine (19.0 mmol) were dissolved in dry tetrahydrofuran (100 mL) and cooled to 0°C. Diisopropyl azodicarboxylate (19.0 mmol) was added dropwise to the stirred solution under an argon atmosphere, and the temperature was kept between 0 and 20°C. The reaction mixture was stirred underan argon at mosphere at 20°C for a further 2–4 h. The reaction was monitored by TLC until completion. The reaction mixture was then evaporated under reduced pressure, and the residue was dissolvedin boiling toluene (100 mL). After cooling to room temperature, the solution was inoculated with a small amount of triphenylphosphineoxide and the solution was kept at 4°C for 24 h. The triphenylphosphineoxide was then filtered off and the filtrate was evaporated under reduced pressure. The residue was crystallized from ethanol or purified by column chromatography on silica (petroleumether: ethyl acetate, 2:1) to afford the pure product.
Reference: [1] Journal of Organic Chemistry, 2007, vol. 72, # 13, p. 5012 - 5015
[2] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 24, p. 6523 - 6535
[3] Journal of Medicinal Chemistry, 2018, vol. 61, # 9, p. 3855 - 3869
  • 17
  • [ 100-39-0 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
  • [ 56025-87-7 ]
YieldReaction ConditionsOperation in experiment
57% With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 16 h; 2,6-Dichloro-9H-purine (10.9g, δOmmol; purchased from Aldrich Chemical Co.) was dissolved in DMF (20OmL) and potassium carbonate (31.9g, 230mmol) added. Benzyl bromide (13.7ml_, 120mmol) was added in portions and the whole stirred at rt under nitrogen for 16h. The mixture was filtered through a short plug of Arbocel.(R). and the filtrate was evaporated in vacuo to give a yellow oil of the N7- (more polar) and N9-benzyl (less polar) purines. This oil was purified by silica gel chromatography using 1 :2:10 EtOAc:acetone:hexane as eluent to give the title compound as a white solid (9.1 g, 57percent).1H NMR (CDCI3, 400MHz): 8.03 (s, 1 H), 7.37-7.41 (m, 3H), 7.29-7.32 (m, 2H), 5.40 (s, 2H).
Reference: [1] Angewandte Chemie, 1993, vol. 105, # 12, p. 1822 - 1823
[2] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 12, p. 3258 - 3261
[3] Patent: WO2006/117670, 2006, A1, . Location in patent: Page/Page column 57
[4] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 15, p. 4622 - 4626
  • 18
  • [ 100-44-7 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
  • [ 56025-87-7 ]
YieldReaction ConditionsOperation in experiment
10%
Stage #1: With potassium carbonate In DMF (N,N-dimethyl-formamide) for 0.333333 h;
Stage #2: for 24 h;
9-Benzyl-2,6-dichloro-9H-purine and 7-benzyl-2,6-dichloro-7H-purine were synthesized according to a method described in the literature: G. Langli; L. L. Gundersen and F. Rise, Tetrahedron 1996, 52 (15), 5625-5638. 2,6-Dichloropurine (18.9 g, 0.10 mol) and potassium carbonate (41.5 g, 0.30 mol) were added to DMF (500 mL) and the mixture was stirred under nitrogen atmosphere for 20 min. Benzylchloride (17.5 mL, 0.15 mol) was added and the mixture was further stirred for 24 hrs. After filtration, DMF was evaporated under reduced pressure, and the obtained reaction mixture was separated and purified by silica gel column chromatography to give 9-benzyl-2,6-dichloro-9H-purine (18.1 g, 64.8 mmol, yield 65percent) and 7-benzyl-2,6-dichloro-7H-purine (2.79 g, 10.0 mmol, yield 10percent).
Reference: [1] Patent: EP1595882, 2005, A1, . Location in patent: Page/Page column 16
[2] Tetrahedron, 1996, vol. 52, # 15, p. 5625 - 5638
  • 19
  • [ 5451-40-1 ]
  • [ 108-88-3 ]
  • [ 79064-26-9 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 7, p. 3710 - 3718
  • 20
  • [ 7285-11-2 ]
  • [ 100-39-0 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
  • [ 56025-87-7 ]
Reference: [1] Patent: US5583137, 1996, A,
  • 21
  • [ 100-44-7 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 12, p. 3805 - 3808
  • 22
  • [ 100-44-7 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
  • [ 56025-87-7 ]
Reference: [1] Tetrahedron Letters, 1995, vol. 36, # 11, p. 1945 - 1948
  • 23
  • [ 100-39-0 ]
  • [ 5451-40-1 ]
  • [ 79064-26-9 ]
  • [ 83545-29-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1982, vol. 30, # 6, p. 2011 - 2019
  • 24
  • [ 5451-40-1 ]
  • [ 100-51-6 ]
  • [ 79064-26-9 ]
  • [ 56025-87-7 ]
Reference: [1] Synthetic Communications, 1993, vol. 23, # 9, p. 1295 - 1305
  • 25
  • [ 5451-40-1 ]
  • [ 120-73-0 ]
  • [ 1681-15-8 ]
Reference: [1] Collection of Czechoslovak Chemical Communications, 2006, vol. 71, # 9, p. 1303 - 1319
  • 26
  • [ 5451-40-1 ]
  • [ 1681-15-8 ]
Reference: [1] Chemistry - A European Journal, 2007, vol. 13, # 6, p. 1754 - 1762
[2] Green Chemistry, 2014, vol. 16, # 3, p. 1077 - 1081
  • 27
  • [ 5451-40-1 ]
  • [ 1839-18-5 ]
YieldReaction ConditionsOperation in experiment
92% With ammonia In methanol at 100℃; for 17 h; Preparation of 2-chloroadenine; 2,6-Dichloropurine (0.877 kg, 4.64 mol) was placed in a 20 L autoclave and treated with methanolic ammonia (7. ON, 6.95 kg). On sealing the autoclave, stirring was initiated and the mixture heated to an internal temperature of 100°C. The reaction mixture was maintained at 100°C for 17 h. before cooling to ambient temperature. Once fully cooled, the autoclave vessel was opened and the reaction mixture diluted with water (3.5 kg). The resulting solid suspension was collected by suction filtration and the filter cake washed with methanol (2 x 0.7 kg) before drying to constant weight in a vacuum oven at 40°C. 2-Chloroadenine was isolated as a pale yellow solid (0.725 kg, 4.28 mol, 92percent).
92% With ammonia In methanol at 100℃; for 21 h; Sealed tube 2,6-Dichloro-9H-purine (VI) (1 g, 5.29 mmcl) was placed in a sealed tube and dissolved in a 7N methanolic ammonia solution (10 mL). The mixture was heated at 100 00 for 21 h. After cooling to rt, the resulting suspension was diluted with water (5 mL) and let under stirring for 30 mm. The solid was filtered, washed with cold water and dried under vacuum. The title compound was isolated as pale yellow solid (830 mg, 92percent).1H NMR (500 MHz, DMSO-d6) ppm 7.62 (br. s., 2 H) 8.09 (s, 1 H) 13.0 (br. s., 1 H). HRMS (ESI+): calcd. for C5H5CIN5 [M + H] 170.0228; found 170.0230.
Reference: [1] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 24, p. 5501 - 5508
[2] Heterocycles, 2013, vol. 87, # 11, p. 2369 - 2384
[3] Nucleosides, Nucleotides and Nucleic Acids, 2005, vol. 24, # 5-7, p. 1127 - 1130
[4] Patent: WO2005/70947, 2005, A1, . Location in patent: Page/Page column 12-13
[5] Patent: WO2018/19681, 2018, A1, . Location in patent: Page/Page column 46; 47
[6] Collection of Czechoslovak Chemical Communications, 1994, vol. 59, # 10, p. 2303 - 2330
[7] Journal of Medicinal Chemistry, 1991, vol. 34, # 9, p. 2877 - 2882
[8] Patent: US6329381, 2001, B1,
[9] Patent: WO2009/34386, 2009, A1, . Location in patent: Page/Page column 59
[10] Journal of Medicinal Chemistry, 2009, vol. 52, # 19, p. 5974 - 5989
[11] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 24, p. 5792 - 5795
[12] Patent: WO2017/197624, 2017, A1, . Location in patent: Paragraph 0092; 0093
  • 28
  • [ 5451-40-1 ]
  • [ 1839-18-5 ]
YieldReaction ConditionsOperation in experiment
100% With ammonia In isopropyl alcohol at 120℃; Intermediate 60: 2-Chloro-1 H-purin-6-amineA mixture of 2,6-dichloro-1 H-purine (5 g) and ammonia solution (79.2 mL, 2M in (isopropanol) was stirred and heated at 120°C in an autoclave overnight. The reaction was cooled and concentrated in vacuo to give the title compound as an off- white solid in quantitative yield. MS calcd for (C5H4CINs)+ = 169/171 MS found (electrospray): (M+H)+ = 170/172 1H NMR ((CDa)2SO): δ 8.14 (1 H, s), 7.66 (2H, s), one exchangeable proton not seen.
Reference: [1] Patent: WO2008/101867, 2008, A1, . Location in patent: Page/Page column 84
  • 29
  • [ 5451-40-1 ]
  • [ 85029-13-6 ]
  • [ 1839-18-5 ]
  • [ 1904-98-9 ]
Reference: [1] Journal of Organic Chemistry, 1983, vol. 48, # 8, p. 1207 - 1210
  • 30
  • [ 5451-40-1 ]
  • [ 1839-18-5 ]
Reference: [1] European Journal of Medicinal Chemistry, 2010, vol. 45, # 12, p. 5678 - 5684
  • 31
  • [ 10310-21-1 ]
  • [ 5451-40-1 ]
YieldReaction ConditionsOperation in experiment
47%
Stage #1: at 10℃;
Stage #2: at -5 - 0℃; for 0.5 h;
To a solution of ZnCl2 (7.0 g,110 mmol) in conc. hydrochloric acid(9.2 mL) at 10 °C was added finely powdered compound 4 (2.3 g,13.6 mmol) with stirring. The resulting stirred mixture was cooledto 5 °C and added NaNO2 (1.27 g, 18.4 mmol) over a period of30 min keeping the temperature below 5 °C. The mixture wasstirred for additional 30 min and was diluted with 12 mL of water.The product was extracted with ethyl acetate (4 x 15 mL). Theorganic phase was washed with water (2 x 7 mL), dried overNa2SO4, and evaporated to dryness to yield 2.37 g (47percent) of finalcompound.
Reference: [1] Nucleosides, Nucleotides and Nucleic Acids, 2011, vol. 30, # 7-8, p. 503 - 511
[2] European Journal of Medicinal Chemistry, 2017, vol. 126, p. 675 - 686
[3] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 5, p. 1140 - 1144
  • 32
  • [ 69-89-6 ]
  • [ 5451-40-1 ]
Reference: [1] Journal of Organic Chemistry, 2011, vol. 76, # 10, p. 4149 - 4153
  • 33
  • [ 10310-21-1 ]
  • [ 110-46-3 ]
  • [ 5451-40-1 ]
Reference: [1] Patent: US2003/144508, 2003, A1,
  • 34
  • [ 10310-21-1 ]
  • [ 5451-40-1 ]
Reference: [1] European Journal of Organic Chemistry, 2018, vol. 2018, # 41, p. 5763 - 5772
  • 35
  • [ 65996-50-1 ]
  • [ 5451-40-1 ]
Reference: [1] Organic Process Research and Development, 2004, vol. 8, # 6, p. 962 - 963
  • 36
  • [ 69-89-6 ]
  • [ 5451-40-1 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1981, vol. 20, # 7, p. 534 - 537
[2] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1980, vol. 19, # 4, p. 332 - 334
[3] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1984, vol. 23, # 12, p. 1286 - 1288
[4] European Journal of Medicinal Chemistry, 2015, vol. 93, p. 414 - 422
  • 37
  • [ 73-40-5 ]
  • [ 5451-40-1 ]
Reference: [1] Nucleosides, Nucleotides and Nucleic Acids, 2011, vol. 30, # 7-8, p. 503 - 511
[2] European Journal of Medicinal Chemistry, 2017, vol. 126, p. 675 - 686
[3] European Journal of Organic Chemistry, 2018, vol. 2018, # 41, p. 5763 - 5772
  • 38
  • [ 5167-14-6 ]
  • [ 5451-40-1 ]
Reference: [1] Archiv der Pharmazie, 1999, vol. 332, # 6, p. 187 - 190
  • 39
  • [ 700-02-7 ]
  • [ 5451-40-1 ]
Reference: [1] Archiv der Pharmazie, 1999, vol. 332, # 6, p. 187 - 190
  • 40
  • [ 97965-44-1 ]
  • [ 5451-40-1 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 5, p. 1140 - 1144
  • 41
  • [ 73-40-5 ]
  • [ 5451-40-1 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 5, p. 1140 - 1144
  • 42
  • [ 149948-29-8 ]
  • [ 5451-40-1 ]
Reference: [1] Nucleosides, Nucleotides and Nucleic Acids, 2011, vol. 30, # 7-8, p. 503 - 511
  • 43
  • [ 190962-00-6 ]
  • [ 5451-40-1 ]
Reference: [1] Nucleosides, Nucleotides and Nucleic Acids, 2011, vol. 30, # 7-8, p. 503 - 511
  • 44
  • [ 149948-30-1 ]
  • [ 5451-40-1 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 126, p. 675 - 686
  • 45
  • [ 124-41-4 ]
  • [ 5451-40-1 ]
  • [ 1198-46-5 ]
YieldReaction ConditionsOperation in experiment
94% at 20 - 80℃; for 1 h; To a solution of 2,6-dichloro-9H-purine (1 g, 5.29 mmol) in MeOH (15 mL) was added a solution of NaOMe 25percent in MeOH (1.26 mL, 5.89 mmol). The mixture was heated to 80 °C for 1 hour followed by cooling to room temperature. The resulting precipitate was filtered, washed with ice-cold MeOH and dried to afford the title compound 920 mg (94percent yield) as a white solid. MS m/z 185.36 [M+1].
Reference: [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 5, p. 584 - 589
[2] Patent: WO2016/130920, 2016, A2, . Location in patent: Page/Page column 123
[3] Tetrahedron Letters, 2015, vol. 56, # 44, p. 6019 - 6021
[4] Molecules, 2011, vol. 16, # 7, p. 5840 - 5860
  • 46
  • [ 67-56-1 ]
  • [ 5451-40-1 ]
  • [ 1198-46-5 ]
YieldReaction ConditionsOperation in experiment
49% Inert atmosphere; Reflux General procedure: To a solution of Na (1.36 equiv) in the appropriate alcohol (20 equiv) was added the appropriately substituted purine under an argon atmosphere. The reaction mixture was stirred at reflux for 2–6 h and then allowed to stir at room temperature overnight under argon. Deionized water (10–20 mL) was added and the reaction mixture was neutralized by addition of acetic acid. The neutralized solution was then extracted with diethyl ether. The ethereal layers were pooled, dried over Na2SO4, concentrated, and dried in vacuum over P2O5 at 25 °C. In most cases, the crude material was purified by column chromatography (CC) over silica gel G.
Reference: [1] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 7, p. 1685 - 1695
  • 47
  • [ 5451-40-1 ]
  • [ 6025-53-2 ]
Reference: [1] Biochemistry, 2013, vol. 52, # 36, p. 6182 - 6196
  • 48
  • [ 5451-40-1 ]
  • [ 85029-13-6 ]
  • [ 1839-18-5 ]
  • [ 1904-98-9 ]
Reference: [1] Journal of Organic Chemistry, 1983, vol. 48, # 8, p. 1207 - 1210
  • 49
  • [ 5451-40-1 ]
  • [ 1904-98-9 ]
Reference: [1] Journal of Organic Chemistry, 1983, vol. 48, # 8, p. 1207 - 1210
  • 50
  • [ 5451-40-1 ]
  • [ 28542-78-1 ]
Reference: [1] Biochemistry, 2013, vol. 52, # 36, p. 6182 - 6196
  • 51
  • [ 5451-40-1 ]
  • [ 13035-61-5 ]
  • [ 3056-18-6 ]
YieldReaction ConditionsOperation in experiment
79% With silica gel 60 In ethyl acetate for 0.5 h; Microwave irradiation 2,6-Dichloropurine (23) (190 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (318 mg, 1 mmol) were dissolved in EtOAc, then 500 mg of silica gel 60 (200-400 mesh) was added. The mixture was concentrated in vacuo and the dry residue was irradiated for 30 min in a domestic microwave oven (120 W). The residue was purified by flash chromatography on silica gel (EtOAc-hexane, 1:2) to yield 24 as yellowish viscous oil (350 mg, 79percent). 1H NMR (CDCl3) δ2.10 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.17 (s, 3H, CH3), 4.42 (d, 2H, CH2-5’), 4.50 (q, 1H, H-4’), 5.59 (t, 1H, H-3’), 5.81 (t, 1H, H-2’), 6.24 (d, 1H, H-1’), 8.33 (s, 1H, H-8). 13C NMR (DMSO-d6) δ 20.53, 20.70, 20.95 (3xCH3), 63.06 (CH2-5′), 70.72 (CH-4’), 73.42 (CH-3’), 81.02 (CH-2’), 86.74 (CH-1’), 131.56 (C-5), 144.10 (C-8), 152.44 (C-6), 152.79 (C-4), 153.55 (C-2), 169.56, 169.74, 170.39 (3xCO). MS (ESI+) m/e: 447.5 (percent100) (M), 449.9 (percent50) (M+2), 451.6 (percent17) (M+4).
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 1, p. 196 - 197
[2] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 3, p. 235 - 239
[3] Journal of Medicinal Chemistry, 2012, vol. 55, # 14, p. 6467 - 6477
[4] Nucleosides, nucleotides and nucleic acids, 2002, vol. 21, # 1, p. 73 - 78
  • 52
  • [ 30571-54-1 ]
  • [ 5451-40-1 ]
  • [ 3056-18-6 ]
Reference: [1] Patent: US5256650, 1993, A,
  • 53
  • [ 5451-40-1 ]
  • [ 123318-82-1 ]
Reference: [1] Nucleosides, Nucleotides and Nucleic Acids, 2000, vol. 19, # 10-12, p. 1861 - 1884
  • 54
  • [ 5451-40-1 ]
  • [ 163042-96-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1994, vol. 37, # 21, p. 3614 - 3621
[2] Patent: KR2015/10195, 2015, A,
  • 55
  • [ 5451-40-1 ]
  • [ 13276-52-3 ]
Reference: [1] Organic Letters, 2015, vol. 17, # 18, p. 4604 - 4607
  • 56
  • [ 5451-40-1 ]
  • [ 58-96-8 ]
  • [ 13276-52-3 ]
Reference: [1] Advanced Synthesis and Catalysis, 2015, vol. 357, # 6, p. 1237 - 1244
  • 57
  • [ 5451-40-1 ]
  • [ 1246529-32-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 13, p. 4377 - 4385
  • 58
  • [ 5451-40-1 ]
  • [ 1382979-44-3 ]
Reference: [1] Organic Process Research and Development, 2016, vol. 20, # 4, p. 751 - 759
[2] Organic Process Research and Development, 2016, vol. 20, # 4, p. 751 - 759
[3] Organic Process Research and Development, 2016, vol. 20, # 4, p. 751 - 759
  • 59
  • [ 870281-86-0 ]
  • [ 5451-40-1 ]
  • [ 870281-82-6 ]
Reference: [1] Patent: WO2016/108206, 2016, A2,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 5451-40-1 ]

Clofarabine Related Intermediates

Chemical Structure| 34371-14-7

[ 34371-14-7 ]

(4S,5R)-4-Hydroxy-5-(hydroxymethyl)dihydrofuran-2(3H)-one

Related Functional Groups of
[ 5451-40-1 ]

Chlorides

Chemical Structure| 7602-01-9

[ 7602-01-9 ]

N-(6-Chloro-7H-purin-2-yl)acetamide

Similarity: 0.75

Chemical Structure| 5177-27-5

[ 5177-27-5 ]

5-Amino-2,4-dichloropyrimidine

Similarity: 0.74

Chemical Structure| 28128-28-1

[ 28128-28-1 ]

8-Chloro-7H-purin-6-amine

Similarity: 0.69

Chemical Structure| 280582-23-2

[ 280582-23-2 ]

4-(2,4-Dichloro-5-pyrimidyl)morpholine

Similarity: 0.68

Chemical Structure| 10132-07-7

[ 10132-07-7 ]

4-Amino-2,6-dichloropyrimidine

Similarity: 0.68

Related Parent Nucleus of
[ 5451-40-1 ]

Purines

Chemical Structure| 7602-01-9

[ 7602-01-9 ]

N-(6-Chloro-7H-purin-2-yl)acetamide

Similarity: 0.75

Chemical Structure| 28128-28-1

[ 28128-28-1 ]

8-Chloro-7H-purin-6-amine

Similarity: 0.69

Chemical Structure| 120-73-0

[ 120-73-0 ]

1H-Purine

Similarity: 0.68

Chemical Structure| 1839-18-5

[ 1839-18-5 ]

2-Chloro-7H-purin-6-amine

Similarity: 0.68

Chemical Structure| 92001-52-0

[ 92001-52-0 ]

6-Chloro-8-methyl-9H-purine

Similarity: 0.67